Background: Maintaining homeostasis is the biological function of negative feedback, a process that plays a wellunderstood role in the biochemistry of antimetabolite drugs. An equally important property of living systemsthe ability to respond to external stimuli by switching rapidly from one state to another-is mediated by positive feedback. Kinetic analysis of multi-enzyme biochemical pathways has shown that pathways containing positive feedback coupled with negative feedback may act as biochemical switching systems in which multiple steady states are possible. Purpose: A computer model was used to study the kinetic effects of antimetabolites that inhibit biochemical pathways at positive feedback sites and to determine whether the kinetics of such systems differed from those of classical antimetabolites. Methods: Kinetics were simulated by microcomputer to model the effects of inhibitors on a simplified metabolic pathway. Results: Antimetabolite drugs that act at positive feedback sites are predicted to display highly nonclassical properties. Three nonclassical properties are kinetically possible. First, the drugs may switch off the pathway at substoichiometric concentrations; classical antimetabolites require stoichiometric levels and sometimes much more. Second, instead of demonstrating classical continuous inhibition, antimetabolite drugs that act at positive feedback sites may give "all-or-none" dose-response curves with discontinuity at a specific value. Inhibitor concentrations below this value would have no overall effect on the system, while inhibitor concentrations at or above this value would give an abrupt transition to an inhibited steady state. Third, the inhibited system may show hysteresis and remain switched off after the inhibitor is removed. Conclusions: These findings suggest that antimetabolites acting at switch points could have kinetic properties very different from those of classical antimetabolites and could provide a noncytotoxic method of switching off pathways in neoplastic cells, perhaps leading to cell stasis. Implications: Experimental validation of these conclusions will require identification of the positive feedback sites of metabolic and signaling pathways and exploration of the effects of inhibitors of these sites. The properties of "switch antimetabolites" should prompt a search for
Inhibition of a metabolic pathway can result in one of three responses: 1) the pathway may adjust to the presence of an inhibitor in a way that maintains an uninhibited flux for the overall pathway, despite the inhibition of one of its component reactions; 2) the pathway may achieve a new, inhibited steady-state flux; or 3) the pathway may be perturbed to a point such that no steady state is possible, in which case the inhibited cell will die (7) . In certain therapeutic situations (e.g., in anti-infective or anticancer chemotherapy), death of the target cell is a desired end point. The goal of therapy with most pharmacological agents is to restore a system, perturbed by some pathological cause, to its former, more normal steady state. For example, the object of therapy may be to return blood pressure, muscle tone, or brain activity to normal.
Most metabolic pathways are controlled by a variety of negative feedback mechanisms (i.e., feedback inhibition), the general effect of which is to resist perturbations by external influences, including drugs. Indeed, this property of homeostasis-the ability to maintain the constancy of the internal milieu in the face of environmental challenges-is generally considered to be one of the basic properties of life. As an example, consider the effects of the antimetabolite fluorouracil (5-FU) on a typical mammalian cell (2) (3) (4) (5) : The active metabolite of 5-FU, 5-fluorodeoxyuridylate (FdUMP), inhibits the enzyme thymidylate synthase, resulting in depletion of its product, thymidylate (dTMP). In turn, this depletion causes depletion of the DNA precursor, thymidine-5'-triphosphate (dTTP), which acts as a potent feedback inhibitor of the enzyme deoxycytidylate deaminase. The release of this enzyme from inhibition (because of dTTP depletion) results in greatly increased production of its product, deoxyuridylate (dUMP), which is a substrate of thymidylate synthase and which competes with F-dUMP for binding to thymidylate synthase. The increase of the cellular dUMP pool (which may be over 100-fold) limits the in-hibitory effectiveness of F-dUMP and tends to displace it from thymidylate synthase.
While the biological function of negative feedback is to maintain homeostasis, an equally important property of living systems is "irritability," i.e., the ability to respond to external stimuli by switching rapidly from one state to another. This behavior is mediated by positive feedback, a property generally known to chemists as "autocatalysis." Autocatalytic systems in chemistry or physics have a reputation for being catastrophic and uncontrollable, as demonstrated by the process in which increasing neutron flux triggers a thermonuclear chain reaction. However, if a positive feedback process is coupled with a negative feedback process, the system acquires the properties of a switch mechanism in which two or more steady states are possible and an appropriate perturbation will switch the system from one state to another. Such systems have been analyzed in detail in electronics and in biology (6, 7) . For example, the digestive enzyme trypsin is secreted from the pancreas into the gut as a larger, inert precursor, trypsinogen. Trypsinogen is converted to trypsin by proteolytic activity in the gut, and once a few active trypsin molecules are formed, they catalyze the conversion of the remaining trypsinogen. The system thus has two stable states: either all trypsinogen and no trypsin (which is how it is stored in the pancreas) or all active trypsin.
In addition to autocatalysis, other system configurations (summarized in Fig. 1 ) may show the property of "multistability" or multiple steady states. In the "cross-catalytic" system of Fig. 1 , the product of the first reaction, B, stimulates the formation of D (the product of the second reaction), which, in turn, stimulates formation of B. Less intuitively obvious is the "cross-inhibitory" system of 1; in this case, B inhibits formation of D, and since D inhibits formation of B, the system as a whole is again autocatalytic. In the Boolean logic of feedback, two negatives make a positive.
Abundant evidence shows that positive feedback systems act as the cell's switching mechanisms. However, there has been no description of the consequences of inhibiting biochemical switches with antimetabolites. This article describes the properties of inhibitors that act on switch systems and shows that their properties display qualitative differences from those of classical antimetabolites. I shall use the term "switch antimetabolites" to describe inhibitors that act on the rate-determining enzymes of biochemical switch mechanisms and shall distinguish them from "classical antimetabolites" such as 5-FU.
Methods
The method used for these studies was computer simulation of a simple metabolic pathway; a diagram of the pathway is shown in Fig. 2 . This pathway can be modeled by a simple computer program known as NETWORK. This program is available from the author, and a listing has been published (/) . In this particular system, the primary source reaction, vl, is subject to feedback activation by low concentrations of its product, B, and to feedback inhibition by high concentrations of B. Various other pathway configurations will also show the appropriate switching behavior, as long as they have positive feedback (or a cross-catalytic process or a cross-inhibitory process) and negative feedback either by the immediate product, B, or by a downstream product, such as C. The parameter values used for the model are summarized in Table 1 . However, the qualitative behavior described by the model can be observed for a wide variety of parameter values.
The NETWORK program integrates the following rate equations: 
The conservation equation for the system is
where B o is initial concentration of B and B, is the concentration at time /. The concentration of A is fixed. These equations are discussed in detail below.
The system of Fig. 2 will reach a steady state when v2 plus v4 equals vl, since B is being produced and consumed at equal rates at these reaction velocities. Fig. 3 shows the sum of v2 and v4 plotted as a function of the concentration of B. Since reactions 2 and 4 utilize B as a substrate, the combined rate increases with increasing concentration of B, eventually
Concn. of B (micromolar) approaching an asymptote. Reaction 2 has a higher-order dependence on the concentration of B, so the early part of the curve is inflected. Reaction vl is activated by low concentrations of B and inhibited by high concentrations of B; it thus reaches a maximum and then declines. Intersections of these two lines are steady states for the system. Fig. 3 shows three such points: SI, S2, and S3. Stability analysis is beyond the scope of the present discussion, but it has been shown that states SI and S3 withstand small perturbations and that S2 is unstable (7) . I shall refer to SI as the OFF steady state and to S3 as the ON state. If this analysis is repeated for different values of the maximum velocity (V mll ) for enzyme 1 (fig. 4, upper panel) , it is clear that for low amounts of enzyme 1, only the OFF steady state is possible (line A), while for high activities of enzyme 1, only the ON state can exist (line E). For intermediate amounts of enzyme 1 (lines B, C, and D) the system may exist in an OFF state or an ON state.
The lower panel of fig. 4 shows the steady states of the system plotted as a function of V,,^ for enzyme 1; the stable lower and upper portions of the curve are linked by an unstable region. Consider this system at the extreme left of the upper limb of the curve, i.e., the ON state corresponding to line B. If enzyme 1 is now infinitesimally inhibited, the sum of v2 and v4 will be greater than vl, so the concentration of B will continue to drop. The system can only reach a steady state by moving to the lower point B, on the OFF limb of the curve. Thus, a small amount of inhibition of enzyme 1 can result in a disproportionate shutdown in total flux through the system. This effect, as well as other related inhibitor effects, has been studied by the technique of metabolic simulation using the NETWORK model. This model simultaneously solves the three rate equations (equations 1, 5, and 6), using the parameter values of Table 1 , for various values of the inhibitors II and 12.
The rate equation for V4 is a simple Michaelis-Menten expression. The v2 equation is a Hill equation with provision for noncompetitive inhibition by 12. The vl rate equation allows for 100-fold activation by the reaction product, B (a first-order interaction), and also for higher-order product inhibition by B. This bimodal effect of a reaction product on an enzyme has been described for a number of important regulatory systems; e.g., the guanosine diphosphate reductase reaction of ribonucleotide reductase is both stimulated (at low concentrations) and inhibited (at high concentrations) by dTTP (8) . Adenosine kinase is both activated and inhibited by its indirect product, adenosine triphosphate (9) . Reaction vl is assumed to be subject to tight-binding inhibition by II, and the expression for fractional activity given in equation 2 is based upon the Morrison equation (10) . Tight-binding inhibition is not a requirement for switching behavior of the system, and the alternative expression (classical noncompetitive inhibition) of equation 3 can be used. However, the classical expression gives no information about stoichiometry, so for determination of stoichiometry of enzyme-inhibitor interaction, the tight-binding inhibition equation must be used.
Results
The All-or-None Dose-Response Curve
The NETWORK model was used to simulate the effects of addition of inhibitors of enzymes 1 and 2. Fig. 5 , A, shows the dose-response curve for effects of 12 (defined as a noncompetitive inhibitor of enzyme 2) on the system. A classical dose-response curve was obtained. A competitive inhibitor of enzyme 2 also gives a conventional doseresponse curve (data not shown). In marked contrast is the predicted effect on the system of a noncompetitive inhibitor of enzyme 1 (Fig. 5, B) . The dose-response curve contains a discontinuity at an II concentration of 0.0139 \iM\ inhibitor concentrations below this value have no effect on the overall flux through the system (which is equal to the rate of reaction 2), and inhibitor concentrations at or above this value give an abrupt transition to a steady state rate of about 16% of the control value. The inhibitor effect is thus an allor-none response. The results shown were calculated with the alternative (classical) expression for fractional activity given in equation 3. Use of the tight-binding inhibitor (Morrison) expression for fractional activity (equation 2) did not alter the qualitative behavior of the system but resulted in the breakpoint occurring at an II concentration of 0.0174 \xM. The predicted nonclassical behavior of inhibitors of reaction 1 is a consequence of this enzyme being subject to positive feedback. This was shown by removing the positive feedback effect of substance B on the system, while the negative feedback effect of B was left intact. The doseresponse curve for a classical noncompetitive inhibitor of reaction 1 in this system is shown in Fig. 5 , C, and is a classical continuous inhibition function. Table 2 shows a study in which the NETWORK system was in its uninhibited (ON) steady state for the first 10 minutes, at which time inhibitor 1 was added at a concentration of 50 nAf. Within 4 minutes, the system switched to the OFF state. At 20 minutes, the inhibitor concentration was returned to zero; however, the value of total flux (v2) increased from only 15.5% of the uninhibited rate to 16.8% of this rate. Although Table 2 shows only 10 minutes of simulation after removal of the inhibitor, the simulation was allowed to run for many hours, and the total flux showed no further tendency to increase. Switching the system back to the ON state requires either the presence of an activator or an increase in the VM1 value (to beyond point D in Fig. 4) . The simulated system thus displayed the property of hysteresis, or in the language of electronics, the system retains a memory of having been inhibited after removal of the inhibitor.
Switch Systems Remember Being Inhibited

Action at Substoichiometric Doses
The classical noncompetitive inhibition equation (equation 3) does not include a term for enzyme concentration. Thus, it can convey no information about stoichiometry of enzyme-inhibitor interactions. However, the Morrison equation (equation 2) includes an enzyme concentration term. The NETWORK model was modified to use this equation to describe inhibition of enzyme 1 by inhibitor 1. With the use of the default conditions (VM1 = 5.172 jjuW/min; k^, for enzyme 1 = 20) the concentration of enzyme 1 in the system is 0.259 \iM. (k cal is the first-order rate constant for conversion of enzyme-substrate complex to enzyme-product complex.) According to the model, this system was inhibited 84% by addition of 0.0175 \>M inhibitor 1. Although this finding is contrary to intuition, the lower panel of Fig. 4 shows that when the system is on the upper cusp at point B, an infinitesimal decrease in activity of enzyme 1 will switch the system to the lower limb of the curve. This large, predicted effect of substoichiometric amounts of inhibitor contrasts sharply with the behavior of classical antimetabolites. For methotrexate to switch off the thymidylate cycle, it is necessary to titrate dihydrofolate reductase and have free inhibitor present in the cell {11), even though methotrexate is a picomolar inhibitor of dihydrofolate reductase. This excess of inhibitor is required because treatment with methotrexate, like that with many classical antimetabolites, results in accumulation within the cell of the competing substrate, which tends to displace the inhibitor. That the substoichiometric effect of inhibitor 1 on the NETWORK system is a consequence of the positive feedback was shown by disabling this feature: 0.0175 \LM II gave no effect on v2, and 15.9 UJW II, a large molar excess, was now necessary to give 84% inhibition of v2.
Switching Between Different States of a Multistable System
The switching behavior of inhibitor 1 in a system with positive feedback is clearly apparent from Table 2 ; the first 10 minutes of the simulation represent the uninhibited ON steady state. After the addition of 50 nM inhibitor, the system was flipped into an OFF state in which the v2 flux was about 15% of the uninhibited value. As seen from 
(micromolar)
either no effect or a full response: It was not possible to obtain, for example, 50% inhibition of this system. This behavior contrasts with the classical behavior of inhibitor 2 in this system. As shown in the upper panel of Table 3 , addition to the system of 1 \\.M 12 gave exactly 50% inhibition. Fig. 5 , C, shows that adding appropriate amounts of 12 to the system can give steady states with any required degree of inhibition. A third kind of behavior is illustrated in the lower panel of Table 3 , in which both positive and negative feedback effects of B on enzyme 1 have been turned off. The uninhibited system achieved a steady state which was close to, but not identical with, that of the system where feedback is present (Table 3 , lower panel, first 15 minutes). Addition to this system of 50 JJUW inhibitor 2 Table 1 and with positive feedback ON. Inhibitor 11 (50 nM) was added at 10 minutes and removed at 20 minutes. II is assumed to be a classical noncompetitive inhibitor. *The upper panel shows the effect of 1 \iM 12 (a noncompetitive inhibitor of enzyme 2) on the NETWORK with positive feedback enabled. 12 (1 \>M) was added at zero time. The lower panel shows a simulation in which both positive and negative feedback effects have been disabled; in the first 15 minutes, the system was allowed to reach its uninhibited steady state, and 50 \LM 12 was added at 15 minutes. resulted in a situation in which the system was unable to achieve a steady state, and substrate B increased without limit (Table 3) . Generally speaking, the lethal effects of classical antimetabolites are the result of biochemical perturbations from which the cell is unable to recover, i.e., situations where no steady state is possible. Experimental studies that provide classical examples of cell death following irreparable biochemical perturbations include those showing huge accumulations of deoxyuridylate after 5-FU treatment (5) and the early literature on thymineless death, reviewed by Cohen (72).
Discussion
With the use of the technique of biochemical simulation, it has been shown that switch antimetabolites differ from classical antimetabolites in several crucial respects. First, classical antimetabolites give a continuous dose-response curve, whereas switch antimetabolites display an "all-ornone" dose-response curve. While this concept is unfamiliar to pharmacologists, it is a familiar one to neurophysiologists: Membrane depolarization in neurones is an all-or-none phenomenon, and although the kinetics of nerve action potentials are still incompletely understood, it is likely that an autocatalytic event is involved.
The second difference between classical antimetabolites and switch antimetabolites is that, in the best case, classical antimetabolites require amounts that are stoichiometric (and often much more) with their target enzyme to switch off a pathway, whereas switch antimetabolites can act at substoichiometric levels. This difference does not contravene the laws of physics: A gentle touch on an ignition switch can turn off a large motor; classical antimetabolites, on the other hand, are more analogous to a roadblock. Nature switches processes on and off in various ways. The first of these is metabolic, as with the trypsinogen-trypsin interconversion whose autocatalytic nature was noted above. Another method is genetic, as observed when lactose from a bacterial growth medium inactivates the lac repressor and turns on not only p-galactosidase, but also galactoside permease. Thus, positive feedback is provided, allowing more lactose to enter the cell. A final example is the nervous system which, like the other switching mechanisms of the body, appears to involve steep dose-response curves and the ability of a small signal to produce a disproportionate response.
The third difference between classical and switch antimetabolites is that for the former (with noncovalently binding inhibitors, at least), removal of the inhibitor reverses the inhibition, while systems inhibited by switch antimetabolites display the property of hysteresis and act as biochemical memories. While experimental examples of biochemical hysteresis are known (6, 75) , the ability of transient exposure to antimetabolite drugs to produce permanent inhibition is still conjectural. This article has shown that permanent inhibition is kinetically possible.
Fourth, classical antimetabolites may perturb their target pathway to a new, inhibited steady state or away from any possible steady state. In the former case, the resulting state need not be a physiological one, and in the latter case, it certainly is not. The effect of switch antimetabolites, conversely, is to flip the system from one available physiological state to another.
Having catalogued the differences between classical and switch antimetabolites, it is necessary to emphasize that switch antimetabolites are not a distinct chemical or mechanistic class of inhibitors; the differences discussed here are a consequence of the action of switch antimetabolites at sites of positive feedback regulation. Experimental validation of these conclusions will require identification of the positive feedback sites of metabolic and signalling pathways and exploration of the effects of inhibitors of these sites.
Numerous questions remain. First is whether any of the existing antimetabolites show evidence of these kinds of properties. It is not yet possible to answer this question with certainty, but some suggestive observations have been reported. One enzyme that certainly has the required feedback properties is ribonucleotide reductase. The 2',2'-difluoro-substituted purine nucleosides, whose 5'-triphosphates are suggested to bind to the dATP regulator site of ribonucleotide reductase, have been reported to have very steep dose-response curves, and transient exposures give very long-lasting effects (14) . Another area of the cell where biochemical switches probably exist includes the signal transduction pathways, and inhibitors of these pathways are beginning to be described. One researcher reported that azatyrosine converted tumor cells to a differentiated phenotype and noted "... surprisingly, these phenotypes appear to be stable; azatyrosine treatment does not need to be continuously administered" (75).
Another unanswered question is where in a positive feedback loop is the best site for pharmacological intervention? Possibilities that should be explored are the substrate site, the activator site, and the feedback inhibition site. Finally, will switch antimetabolites be cytotoxic or cytostatic? If they do indeed trigger transitions between alternative physiological states, they may in fact change the behavior of transformed cells without causing cytotoxicity and without the need for continuous administration. All of these questions, and the properties of switch antimetabolites in general, should be considered as new targets for drug design are contemplated.
